Trials Starting Soon
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus with Radiofrequency Ablation
If you are a male or female >18 years old with a previously confirmed diagnosis of Barrett's esophagus (BE) with or without dysplasia requiring radiofrequency ablation (RFA) that resulted in documented complete resolutions of BE within the past 2 years, you might be eligible for the study. The study will evaluate whether supplementation with aspirin 325 mg/day for 12 months is safe and reduces the expression of CDX2 mRNA (a biomarker that has been associated with the risk of developing BE) in comparison to placebo after successful RFA. The study is sponsored by the National Cancer Institute (NCI).
- Study participants must be 18 years or older with previous confirmed diagnosis of BE with or without dysplasia requiring RFA with documented resolution of BE within the past 24 months.
- Women in the child-bearing period who are willing to participate must have a negative pregnancy test in the blood within the prior 7 days to their inclusion in the study.
- Study participants must not be on chronic use of aspirin or other similar NSAIDS agents in the past 3 months. They must not be on anticoagulant drugs (blood thinners) as well. Participants who are on certain drugs might not be eligible to participate in the study (contact the study coordinator for more details).
- Patients who are allergic to aspirin or similar products are ineligible to participate. Those with certain uncontrolled illnesses might not be eligible to participate (contact the study coordinator for specific details).
- Patients with known cancer diagnosis or treatment recently might not be eligible to participate (contact the study coordinator for specific details).
- Patients with major surgery in the upper digestive tract or those with esophageal narrowing are excluded from the study.
- Patients with renal failure and HIV are ineligible to participate
- Pregnant and breast-feeding women are ineligible to participate.
This study is conducted by Dr. V. Raman Muthusamy. The study is coordinated by Amanda Moralde.
If interested or in case you have any inquiries, please call 310-267-3636.
Protocol ID: IRB# 16-000628